





In 2024, 100 participants, recruited Sydney, NSW, were interviewed.



The median age in 2024 was 27, and 66% identified as male.




In the 2024 sample, 33% were current students, 34% were employed full time and 24% were unemployed.




Participants were recruited on the basis that they had consumed ecstasy and/or other illicit stimulants at least monthly in the past 6 months.


DRUG-RELATED HARMS AND RISKS




Among recent drivers, 46% reported driving a vehicle within 3 hours of consuming illicit drugs and 22% while over the legal limit of alcohol.



Percentage who reported past year non-fatal depressant and stimulant overdose.




Percentage who obtained an AUDIT score of eight or more, indicative of past year hazardous alcohol use.



In 2024, 78% reported using two or more drugs on the last occasion of ecstasy or related drug use: the most commonly used combination of drug classes was depressants and stimulants (22%).

OTHER BEHAVIOURS



Among those who reported a mental health problem, the three most common mental health issues were anxiety, depression and ADHD.



Percentage who self-reported mental health problems and treatment seeking in the six months preceding interview.




Percentage who reported that they or someone else had tested the content and/or purity of their illicit drugs in Australia in the past year.



21% of the sample reported experiencing stigma because of their illicit drug use in the six months preceding interview, most commonly from police.

PAST 6 MONTH USE OF SELECT DRUGS

Ketamine



LSD




Hallucinogenic mushrooms/psilocybin



GHB/GBL/1,4-BD




Amyl Nitrite






Nitrous oxide (nangs)







E-cigarettes






ECSTASY



METHAMPHETAMINE



COCAINE



CANNABIS AND/OR CANNABINOID-RELATED PRODUCTS

